At the annual American Association of Neurological Surgeons meeting, NuVasive (NUVA) will launch new products including AttraX® Putty Biotextured™ bone graft, the Reline® Modular system, next-gen MAS® TLIF 2 technology, etc.
- AttraX, which recently received FDA 510(k) clearance, is already marketed internationally. This next-gen synthetic biologic product is indicated as an autograft extender in the posterior lateral spine.
- Reline is part of NUVA's Integrated Global Alignment (iGA™) platform, and is designed to improve visualization and access to the intervertebral disc in TLIF and PLIF.
- The Monolith™ Corpectomy system is a modular, imaging-friendly PEEK implant indicated for use in T1-L5 with supplemental fixation.
For 1Q16, NUVA reported revenue of US $215.1MM, +11.8% from 1Q15, including a quarter of sales from newly-acquired Ellipse Technologies products.
Sources: NuVasive, Inc.; ORTHOWORLD Inc.